Check out which companies are making headlines before the bell:
Home Depot—The home improvement retailer matched estimates with adjusted quarterly profit of $1.71 per share, with revenue and comparable-store sales beating Street forecasts. Home Depot also raised its sales and profit forecast for the full year.
Wal-Mart—The retail giant missed estimates by 4 cents with quarterly profit of $1.08 per share, though revenue did beat Street forecasts. Wal-Mart also cut its full-year guidance as it pays higher wages and invests more in its U.S. business.
Dick's Sporting Goods—The sporting goods retailer came in 2 cents above estimates with quarterly profit of 77 cents per share, while revenue was in line with estimates. Dick's also raised its full-year forecast.
Urban Outfitters—The retailer reported quarterly profit of 52 cents per share, 3 cents above estimates. Revenue, however, missed forecasts, as did the same-store sales increase of four percent. Investors are particularly focused on the latter figure, ahead of the back-to-school shopping season.
Brookfield Asset Management—Brookfield is buying Australian freight company Asciano for $6.6 billion. It's the biggest ever acquisition by a Canadian firm in Australia.
Petrobras—Petrobras may reportedly pay a record penalty of $1.6 billion or more to settle U.S. probes into a corruption scandal at the Brazilian energy company. Reuters did add that the settlement process could take two to three year to complete.
McDonald's—McDonald's was the top choice of "Breakfastarians," according to a survey obtained by Reuters. "Breakfastarians" is a group of consumers who want breakfast food at any time of day, and McDonald's was the top choice of 41 percent of those surveyed. Subway came in second at 34 percent, followed by IHOP, Burger King, and Starbucks.
Sprint—The wireless carrier is ending two-year contracts and changing to a business model in which customers lease their smartphones.
Abercrombie & Fitch—Abercrombie is set to announce a management restructuring today, according to The Wall Street Journal. According to the report, the company will create six new positions which will report to Abercrombie brand president Christos Angelides.
Esperion Therapeutics—The drug maker's lead drug—designed to reduce cholesterol—remains on track to begin Phase 3 studies. That follows the removal of a partial clinical hold on the drug by the FDA last month.
Coach—Coach was upgraded to "buy" from "hold" at Jefferies and added to the firm's "Franchise Pick" list, saying the company's turnaround efforts are taking hold and that the overall handbag market is set to reaccelerate after a recent slowdown.
Questions? Comments? Email us at firstname.lastname@example.org